Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Cancer

Disease Area Cancer

Image of the Month

| Charlotte Barker

A protective nest of fibrotic scar tissue surrounding pancreatic tumors

Disease Area Cancer

Moonshot... Or Just Moon Gazing?

| William A Hyman

Is the "Cancer Moonshot" approach to research really a viable solution?

Research Field Cancer

Retrotransposon Risks

| William Aryitey

Retrotransposons can initiate oncogenesis, with an increased risk in certain populations

Tools & Techniques Cancer

Cancer Fighter PILOT

| Charlotte Barker

A novel PDX screening technique has uncovered new molecular drivers for PDAC

Tools & Techniques Cancer

The PDAC Key

| Michael Schubert

Pancreatic cancer cells don’t seem to rely on EMT for metastasis – but it plays a key role in their ability to resist our best chemotherapy options

Tools & Techniques Cancer

Tracking the Transition

| Dingcheng Gao

A triple-transgenic mouse model allows researchers to trace the lineage of EMT tumor cells, and reveals the transition’s surprising lack of significance in metastasis

Tools & Techniques Cancer

Proceed With Caution

| Shyamala Maheswaran

Two recent studies on EMT may revise the field’s understanding of the process – but it’s important to keep in mind the limitations.

Outside the Lab Cancer

Oncogenetic Pioneer

| Robert A. Weinberg

Sitting Down With… Robert A. Weinberg, founding member of the Whitehead Institute for Biomedical Research and Professor of Biology at the Massachusetts Institute of Technology, USA.

Outside the Lab Cancer

Cancer Control on a Shoestring

| Rengaswamy Sankaranarayanan

As cancer rates continue to climb, low and middle income countries are ramping up prevention and screening efforts.

Disease Area Cancer

In Good Company

| Bharathi Vennapusa

What does it take to create a competitive companion diagnostic? Bharathi Vennapusa outlines her role in the development and approval of the ALK CDx – a fully-automated immunohistochemistry assay that identifies lung cancer patients who may be eligible for treatment with Pfizer’s Xalkori (crizotinib).

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register